In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The New Norway: “More Research And More Companies” – The Inven2 View

Executive Summary

Plummeting oil prices prompted Norway’s politicians to look at developing other industries. As a result, several programs have been launched to incentivize new areas, including biopharma and diagnostics.

You may also be interested in...



CardiNor Leads The Charge As Norway Gets Behind Life Sciences

Norwegian start-up CardiNor is developing a new cardiovascular biomarker, and is hopeful of attracting cash in a country where investor traditions are undergoing some changes. The financial pressures caused by falling oil prices have brought renewed attention to life science companies.

Biosecurity Centre And ‘Test And Trace’ To Augment UK’s COVID-19 Test Momentum

The UK has added important new capabilities to its COVID-19 monitoring and control effort and those running it promise a “world class system” by late summer.

Fact File: European COVID-19 Focus Shifts To Managing The ‘New Normal’

The evolution of how and where patients receive their care has received an unexpected boost from the COVID-19 crisis. Coronavirus volume testing challenges persist, but the global medtech industry is now looking beyond the crisis toward a return to “normal” business.

Topics

Related Companies

UsernamePublicRestriction

Register

IV124437

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel